SAN FRANCISCO — Are we entering a world in which all of the exciting new therapeutics come from China?
That question and variations of it could be heard at coffee meetings and late-night cocktail parties this week during the J.P. Morgan Healthcare Conference.
Just days before plane-fulls of biopharma executives and investors touched down in San Francisco, a flurry of companies launched with drug candidates from China. And year-end reports from investment banks laid bare just how much that type of dealmaking had dominated the industry last year. More than a third of the therapeutic molecules bought by pharma companies came from China last year, according to a report from Stifel. That number was zero four years ago.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in